Cysteamine + CF -- Research Links

• Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation:
  Read more:http://www.tandfonline.com/doi/abs/10.4161/15548627.2014.973737#.VJGv4AkO
• Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis
  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260250/ 

• "They will receive oral cysteamine, with increasing dose (from 450mg once daily to 450mg four times daily) over three weeks, they will remain on 450mg four times daily for two weeks. Sputum cysteamine will be quantified after two weeks of full dose cysteamine 450mg qds."
  Link: http://public.ukcrn.org.uk/search/StudyDetail.aspx

• First Study of Oral Cysteamine in Cystic Fibrosis:
  "Cysteamine is a licensed drug used in the treatment of cystinosis for more than 20 years. Laboratory based work suggests that cysteamine may be a beneficial adjunct to conventional antibiotic treatment in CF. Cysteamine is a potent mucolytic, it disrupts biofilms, it is antimicrobial, and synergises with other antibiotic agents, broadening their spectrum of activity, delivers a post-antimicrobial effect and reverses antibiotic resistance (even in multi-drug resistant bacteria)."
  Link: https://clinicaltrials.gov/ct2/show/NCT02212431?term=cystagon+cystic+fibrosis&rank=1

• Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR.
  Read more: http://www.ncbi.nlm.nih.gov/pubmed/23800975

• Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease.
  Read More: http://www.ncbi.nlm.nih.gov/m/pubmed/21395631/

• Restoring defective autophagy as a novel therapeutic strategy in Cystic Fibrosis. Read More: http://flipper.diff.org/apptags/items/6986

• Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. 
  Read More: http://www.ncbi.nlm.nih.gov/pubmed/?term=Villella+CDD+2013

• Cysteamine for the treatment of cystic fibrosis. 
  Read More: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/03/WC500164313.pdf

• Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect. 
  Read More: http://www.ncbi.nlm.nih.gov/pubmed/?term=Targeting+the+intracellular+environment+in+cystic+fibrosis%3A+restoring+autophagy+as+a+novel+strategy+to+circumvent+the+CFTR+defect

• Cysteamine been patented by Seattle children's as a way to reverse scar tissue in kidney disease, lung disease, heart disease. 
  Read More: http://www.google.com/patents/US20140275279
  
  Other CF related articles:

• Mechanism-based corrector combination restores DF508 CFTR folding and functionRead more: http://www.nature.com/nchembio/journal/v9/n7/full/nchembio.1253.html